TransMedics Group (NASDAQ:TMDX) Stock Rating Upgraded by Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms have also commented on TMDX. Needham & Company LLC upped their target price on TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a report on Friday. TD Cowen reissued a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research report on Friday. Barclays started coverage on TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. Finally, Zacks Research upgraded TransMedics Group from a “strong sell” rating to a “hold” rating in a research note on Monday, November 2nd. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $118.60.

TransMedics Group Stock Performance

TMDX stock opened at $88.24 on Friday. The firm has a market cap of $3.05 billion, a P/E ratio of 23.91, a P/E/G ratio of 1.18 and a beta of 2.14. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The stock’s 50 day simple moving average is $79.61 and its 200 day simple moving average is $93.17. The company has a current ratio of 4.53, a quick ratio of 4.15 and a debt-to-equity ratio of 1.46.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. The company had revenue of $203.01 million for the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a net margin of 19.85% and a return on equity of 13.30%. The company’s revenue for the quarter was up 41.1% on a year-over-year basis. During the same period last year, the firm posted $0.66 EPS. As a group, equities research analysts predict that TransMedics Group will post 1.50 EPS for the current year.

Insiders Place Their Bets

In other news, Director David Weill acquired 1,336 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. increased its stake in shares of TransMedics Group by 24.9% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock valued at $73,000 after purchasing an additional 174 shares during the period. Plan A Wealth LLC raised its holdings in shares of TransMedics Group by 3.9% during the third quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock valued at $448,000 after buying an additional 203 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of TransMedics Group by 4.8% during the second quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares during the last quarter. HB Wealth Management LLC boosted its position in shares of TransMedics Group by 1.5% during the second quarter. HB Wealth Management LLC now owns 15,062 shares of the company’s stock worth $1,000,000 after buying an additional 219 shares during the period. Finally, D.A. Davidson & CO. boosted its position in shares of TransMedics Group by 1.4% during the third quarter. D.A. Davidson & CO. now owns 16,060 shares of the company’s stock worth $1,340,000 after buying an additional 228 shares during the period. Institutional investors own 99.67% of the company’s stock.

Trending Headlines about TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.